191 related articles for article (PubMed ID: 12876631)
21. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.
de Bruijne EL; Darwish Murad S; de Maat MP; Tanck MW; Haagsma EB; van Hoek B; Rosendaal FR; Janssen HL; Leebeek FW;
Thromb Haemost; 2007 Feb; 97(2):181-5. PubMed ID: 17264944
[TBL] [Abstract][Full Text] [Related]
22. Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity.
Hamdy M; Shaheen IA; Khallaf M; Selim YMM
Pediatr Blood Cancer; 2024 Jun; 71(6):e30959. PubMed ID: 38520679
[TBL] [Abstract][Full Text] [Related]
23. Association of TAFI gene polymorphisms with severity of coronary stenosis in stable coronary artery disease.
Rattanawan C; Komanasin N; Settasatian N; Settasatian C; Kukongviriyapan U; Intharapetch P; Senthong V
Thromb Res; 2018 Nov; 171():171-176. PubMed ID: 30321704
[TBL] [Abstract][Full Text] [Related]
24. Genetic variations in the thrombin-activatable fibrinolysis inhibitor gene and risk of cardiovascular disease: a systematic review and meta-analysis.
Shi J; Zhi P; Chen J; Wu P; Tan S
Thromb Res; 2014 Sep; 134(3):610-6. PubMed ID: 25042727
[TBL] [Abstract][Full Text] [Related]
25. Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasma TAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD).
Verdú J; Marco P; Benlloch S; Sanchez J; Lucas J
Thromb Haemost; 2006 Mar; 95(3):585-6. PubMed ID: 16525595
[No Abstract] [Full Text] [Related]
26. Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome.
Tàssies D; Roqué M; Monteagudo J; Martorell T; Sionis A; Arzamendi D; Heras M; Reverter JC
Thromb Res; 2009 Nov; 124(5):614-8. PubMed ID: 19699511
[TBL] [Abstract][Full Text] [Related]
27. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.
Leebeek FW; Goor MP; Guimaraes AH; Brouwers GJ; Maat MP; Dippel DW; Rijken DC
J Thromb Haemost; 2005 Oct; 3(10):2211-8. PubMed ID: 16092924
[TBL] [Abstract][Full Text] [Related]
28. Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study.
Fawzy MS; Mohammed EA; Ahmed AS; Fakhr-Eldeen A
Meta Gene; 2015 Jun; 4():73-84. PubMed ID: 25893174
[TBL] [Abstract][Full Text] [Related]
29. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.
Franco RF; Fagundes MG; Meijers JC; Reitsma PH; Lourenço D; Morelli V; Maffei FH; Ferrari IC; Piccinato CE; Silva WA; Zago MA
Haematologica; 2001 May; 86(5):510-7. PubMed ID: 11410415
[TBL] [Abstract][Full Text] [Related]
30. A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease.
Kremer Hovinga JA; Franco RF; Zago MA; Ten Cate H; Westendorp RG; Reitsma PH
J Thromb Haemost; 2004 Jan; 2(1):54-7. PubMed ID: 14717966
[TBL] [Abstract][Full Text] [Related]
31. Reduced thrombin activatable fibrinolysis inhibitor and enhanced proinflammatory cytokines in acute coronary syndrome.
Pang H; Zhang C; Liu F; Gong X; Jin X; Su C
Med Intensiva; 2017 Nov; 41(8):475-482. PubMed ID: 28038785
[TBL] [Abstract][Full Text] [Related]
32. Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis.
Lau HK; Segev A; Hegele RA; Sparkes JD; Teitel JM; Chisholm RJ; Strauss BH
Thromb Haemost; 2003 Dec; 90(6):1187-91. PubMed ID: 14652655
[TBL] [Abstract][Full Text] [Related]
33. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
Ricart JM; Ramón LA; Vayá A; España F; Santaolaria ML; Todolí J; Castelló R; Fontcuberta J; Estellés A
Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
[TBL] [Abstract][Full Text] [Related]
34. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors.
Juhan-Vague I; Renucci JF; Grimaux M; Morange PE; Gouvernet J; Gourmelin Y; Alessi MC
Arterioscler Thromb Vasc Biol; 2000 Sep; 20(9):2156-61. PubMed ID: 10978263
[TBL] [Abstract][Full Text] [Related]
35. Impact of genetic polymorphisms in thrombin activatable fibrinolysis inhibitor (TAFI) on venous thrombosis disease: A meta-analysis.
Qian K; Xu J; Wan H; Fu F; Lu J; Lin Z; Liu Z; Liu H
Gene; 2015 Sep; 569(2):173-81. PubMed ID: 26071134
[TBL] [Abstract][Full Text] [Related]
36. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients.
Fernandez-Cadenas I; Alvarez-Sabin J; Ribo M; Rubiera M; Mendioroz M; Molina CA; Rosell A; Montaner J
J Thromb Haemost; 2007 Sep; 5(9):1862-8. PubMed ID: 17723126
[TBL] [Abstract][Full Text] [Related]
37. Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies--a pilot study.
Sucker C; Hetzel GR; Farokhzad F; Dahhan F; Schmitz M; Kurschat C; Grabensee B; Maruhn-Debowski B; Zotz R; Scharf R
Nephrol Dial Transplant; 2007 May; 22(5):1347-50. PubMed ID: 17327284
[TBL] [Abstract][Full Text] [Related]
38. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis.
Martini CH; Brandts A; de Bruijne EL; van Hylckama Vlieg A; Leebeek FW; Lisman T; Rosendaal FR
Br J Haematol; 2006 Jul; 134(1):92-4. PubMed ID: 16803573
[TBL] [Abstract][Full Text] [Related]
39. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
Yener S; Akarsu M; Demir T; Akinci B; Sagol O; Bayraktar F; Ozcan MA; Tankurt E; Yesil S
J Endocrinol Invest; 2007 Nov; 30(10):810-9. PubMed ID: 18075282
[TBL] [Abstract][Full Text] [Related]
40. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels.
Santamaría A; Oliver A; Borrell M; Mateo J; Belvis R; Martí-Fábregas J; Ortín R; Tirado I; Souto JC; Fontcuberta J
Stroke; 2003 Oct; 34(10):2387-91. PubMed ID: 12947154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
